Wnt信号通路与肝纤维化潜在治疗药物的研究现状  

Advances in Wnt signaling pathway and potential therapeutic drugs of liver fibrosis

作　　者：孙旭[1] 熊芬[1] 黄育生[2] 闫雪[1] 苏芬丽[1] 蔡庆群[1] 丘振文[1] SUN Xu;XIONG Fen;HUANG Yu-sheng;YAN Xue;SU Fen-li;CAI Qing-qun;QIU Zhen-wen(Department of Pharmacy,The First Affiliated Hospital of Guangzhou University of Chinese Medicine,Guangzhou 510405,Guangdong Province,China;Lingnan Medical Research Center of Guangzhou University of Chinese Medicine,Guangzhou 510405,Guangdong Province,China)

机构地区：[1]广州中医药大学第一附属医院药学部,广东广州510405 [2]广州中医药大学岭南医学研究中心,广东广州510405

出　　处：《中国临床药理学杂志》2021年第22期3180-3184,共5页The Chinese Journal of Clinical Pharmacology

基　　金：广东省中医药管理局基金资助项目(20201094)。

摘　　要：肝纤维化是肝长期受到各种慢性炎症刺激导致肝星状细胞激活,细胞外基质过度沉积的一种可逆性病理过程。近期较多研究证实肝纤维化模型中存在Wnt信号通路的异常激活,靶向抑制Wnt通路可阻止肝星状细胞的活化及增殖,从而达到抗纤维化的作用。本文就Wnt信号通路抗肝纤维化的潜在治疗药物进行综述,以期为临床和基础研究抗肝纤维化提供新思路。Hepatic fibrosis is a reversible pathological process in which the liver cells has been subjected to long periods of various chronic injuries leading to the activation of hepatic stellate cells and excessive accumulation of extracellular matrix.Recent studies have confirmed that hepatic fibrosis models have abnormal activation of Wnt/β-catenin signal pathway and targeted inhibition of the Wnt signaling pathway can prevent the activation and proliferation of hepatic stellate cells and thus achieve an antifibrogenic effect.This paper reviews the potential therapeutic drugs of Wnt signaling pathway against liver fibrosis,with a view to providing new ideas for clinical and basic research on hepatic fibrosis.

关 键 词：肝纤维化 肝星状细胞 WNT信号通路 

分 类 号：R97[医药卫生—药品]